Navigation Links
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT
Date:7/10/2014

compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company utilized the services of paid stock promoters to inflate its share price; (ii) contrary to the Company's representations, preparations were not underway for a Phase 3 study for PV-10; and (iii) the Company improperly referred to PV-10 as obtaining a Breakthrough Therapy Designation ("BTD"), and otherwise implied that obtaining that status was inevitable.

On January 23, 2014, an article was published on TheStreet.com, accusing Provectus of artificially inflating the price of its stock by making false representations related to the commencement of Phase III clinical trials. 

On this news, the Company's shares declined $3.35, or over 64%, to close at $21.87 on January 23, 2014.

Prior to May 20, 2014, the Company's website improperly described its PV-10 drug as a "breakthrough" drug for skin cancer, prior to the FDA's designation of the drug as such.  On May 20, 2014, the Company updated its website and changed the description of PV-10 to "An Investigational Drug for Cancer" and included language clearly indicating that the drug was still awaiting BTD designation by the FDA.

On this news, Provectus securities declined $0.31 per share, or over 10%, to close at $2.70 per share on May 20, 2014.

On May 21, 2014, an article was published on SeekingAlpha.com alleging that the Company was tied to stock promoters that improperly marketed the Company's stock to unsophisticated retail investors, thus artificially inflating the price of the Company's shares.  The article noted that trading in many of the other companies associated with these stock promoters was recently halted by the SEC.  That same day, Provectus issued a press release refuting the allegations of the SeekingAlpha.com article.  Provectus specifically noted that PV-10, its investigational metasta
'/>"/>

SOURCE Pomerantz LLP
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. Acquisition of BioClinica, Inc. by JLL Partners, Inc. May Not Be in BioClinica, Inc. Shareholders Best Interests
2. Medbox Communicates with Shareholders, Comments on Pending Transition to OTC Bulletin Board, and Announces Appearance on Fox Business News Channel
3. Investigation of American Oriental Bioengineering, Inc. by Securities Lawyers at Goldfarb LLP Law Firm for Potential Shareholder Claim
4. Red alert: Body kills spontaneous blood cancers on a daily basis
5. Media alert: Society of Interventional Radiologys Annual Scientific Meeting
6. Webcast alert: Molecular Medicine Institute to give new hope to pediatric patients
7. Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors
8. BrightFocus Foundation announces 55 new grantees in Alzheimers and vision research
9. Elsevier Announces the launch of open access journal: New Negatives in Plant Science
10. Institute of Physics announces 2014 award winners
11. Elsevier announces the launch of a new journal: Current Opinion in Behavioral Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... closer to eliminating periodontal disease through their work to ... the disease from spreading throughout the mouth. ... a mouth rinse, toothpaste or tooth varnish to prevent ... PhD, associate dean for research and enterprise, UofL School ...
... shown for the first time that Marine Protected Areas ... actually work. Their study, based on 21 years, monitoring ... of Applied Ecology , reveals that a marine sanctuary off ... dolphins one of the rarest dolphins in the world. ...
... growing body of research shows that birds and other animals change ... of traffic or the hum of machinery. But human ... plants or eat or disperse their seeds, human noise can have ... the March 21, 2012, issue of the journal Proceedings of ...
Cached Biology News:UofL research holds promise of therapeutic approach for gum disease 2Size matters: Large Marine Protected Areas work for dolphins 2Human noise has ripple effects on plants 2Human noise has ripple effects on plants 3
(Date:8/3/2015)... , August 3, 2015 At ... Portland Hospital waved the shortfall of Jude ... stand normally for the first time.      ... http://photos.prnewswire.com/prnh/20150803/254229 ) The Selective Dorsal ... allowing him to carry out his wish to kick ...
(Date:8/3/2015)... -- Merck KGaA, Darmstadt, Germany ,  a ... the healthcare, life science and performance materials sectors, announced ... and launch of promising new fullerene derivatives for the ... Germany , is pursuing many projects ... Novel derivatives: highly stable, easy to process and cost ...
(Date:8/3/2015)... 2015 E-QURE Corp. (OTCQB: EQUR), ... Bio-electrical Signal Therapy device ("BST Device"), a new and ... heal chronic wounds, today announced that the Company has ... distributor specializing in medical devices, for the marketing and ... a 70 years old, sales, marketing and distribution company ...
(Date:8/3/2015)... Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... on the development of autologous cell therapies, announced today that ... the InvestMNT conference held in Minneapolis, Minnesota ... time. Hall,s presentation will highlight RepliCel,s 18-month milestones including CE ... Europe , clinical data from both RCT-01 (tendon) ...
Breaking Biology Technology:Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2
... Board Authority to Implement Reverse Stock Split and ... Shares and Authorized Shares, NEW HAVEN, Conn., Feb. 13 ... Special Meeting of,Stockholders was held at the Omni Hotel in ... meeting, shareholders voted to approve amendments to the,Company,s Restated Certificate ...
... Feb. 13 Rocky Mountain Biosystems, Inc.(R),(RMBI), ... receipt of a,grant award of approximately $600,000 ... Allergy and Infectious Diseases at the National ... Vaccination Electromechanical,(SAVE) technology for influenza vaccination. In ...
... WHAT: Free infant CPR training and certification for expectant parents ... Company. The training will also include a basic course on cord ... 11915 La Grange Avenue (near Bundy and Olympic) ... 10 a.m. to 12 noon (Breakfast will be served), ...
Cached Biology Technology:Vion Pharmaceuticals Holds Special Meeting of Stockholders 2Vion Pharmaceuticals Holds Special Meeting of Stockholders 3NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza 2FREE Infant CPR Training and Cord Blood Banking 101 for Expectant Parents 2